Anavex Life Sciences Corp(AVXL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.15 | Insider Own | 1.71% | Shs Outstand | 92.7M | Perf Week | -10.53% |
| Market Cap | 0.11B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 91.1M | Perf Month | -37.04% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | - | Inst Own | 39.86% | Short Float | 13.77% | Perf Quarter | -59.66% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | -3.52% | Short Ratio | 12.03 | Perf Half Y | -64.16% |
| Sales | 0.00B | P/B | 0.98 | EPS next 5Y | - | ROA | -11.7% | Short Interest | 12.55M | Perf YTD | -66.57% |
| Book/sh | 1.21 | P/C | 0.93 | EPS past 3/5Y | 4.47% -3.79% | ROE | -12.8% | 52W High | -85.75% ($8.35) | Perf Year | -85.18% |
| Cash/sh | 1.28 | P/FCF | - | Sales past 3/5Y | - | ROIC | -11.58% | 52W Low | 4.39% ($1.14) | Perf 3Y | -78.36% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 73.28% | Gross Margin | - | Volatility(W/M) | 5.7% 7.55% | Perf 5Y | -93.65% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.11 | Perf 10Y | -59.8% |
| Dividend Ex-Date | - | Quick Ratio | 15.62 | EPS Q/Q | 154.29% | Profit Margin | - | RSI (14) | 20.79 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 15.62 | Sales Q/Q | - | SMA20 | -15.35% ($1.41) | Beta | 1.18 | Target Price | $20 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/25 | SMA50 | -44.47% ($2.14) | Rel Volume | 1.15 | Prev Close | $1.3 |
| Employees | 34 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -61.52% ($3.09) | Avg Volume(3M) | 1.04M | Price | $1.19 |
| IPO | 2006/8/2 | Option/Short | Yes/Yes | Trades | 4519 | Volume | 1,198,079 | Change | -8.46% |
Anavex Life Sciences (AVXL) is a clinical-stage biotech company developing treatments for central nervous system disorders, including Alzheimer's disease and Rett syndrome, through an oral drug candidate that targets the sigma-1 receptor. Headquartered in the United States, its business value is largely concentrated on the late-stage clinical development and regulatory pathway of its key drug candidate.
Over the past 1 year, on the lower side
86% below its 1-year high.
Traded about as much as usual. That is 115% of its average volume.
AVXL has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -93.7%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 39.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #345 of 597 in the industry
Based on market cap of $110M.
NKTX#343 Nkarta Inc $112M PER - 
NERV#344 Minerva Neurosciences Inc $111M PER - AVXL#345 Anavex Life Sciences Corp $110M PER - 
PYPD#346 Polypid Ltd $109M PER - 
ANIX#347 Anixa Biosciences Inc $108M PER - 
FAQ
What kind of company is AVXL?
AVXL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AVXL?
The market cap of AVXL is approximately $110M, ranking 4,403 within its sector.
What is the 52-week high and low for AVXL?
AVXL has recorded a 52-week high of $8.35 and a low of $1.14.
